Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Recurrent GlioblastomaRecurrent Gliosarcoma

Interventions

BIOLOGICAL

Atezolizumab

Given IV

DRUG

Cabozantinib

Given PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER